微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 64.39% | -4.92% | -3.03% | 40/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 66.4% | -3.54% | -0.86% | 37/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 66.98% | -3.64% | -0.6% | 37/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 67.38% | 0.71% | -0.5% | 36/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 67.72% | 1.1% | -1.62% | 36/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 68.84% | 3.25% | -0.97% | 35/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 69.51% | 5.38% | 3.89% | 31/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 66.91% | -1.3% | -0.12% | 40/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 66.99% | -0.89% | 0.47% | 38/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 66.67% | 0.62% | 1.08% | 38/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 65.96% | -0.87% | -2.7% | 36/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 67.79% | -2.79% | 0.3% | 38/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 67.59% | -3.17% | 2% | 38/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 66.26% | -5.15% | -0.42% | 41/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 66.54% | -6.69% | -4.58% | 39/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 69.74% | 0.1% | -0.09% | 38/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 69.8% | -2.02% | -0.09% | 37/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 69.86% | 0.81% | -2.04% | 41/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 71.31% | 4.49% | 2.36% | 37/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 69.67% | 0.72% | -2.2% | 43/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 71.23% | -1.43% | 2.8% | 34/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 69.3% | -5.14% | 1.54% | 38/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 68.25% | 1.4% | -1.33% | 33/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 69.17% | -8.38% | -4.29% | 40/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 72.27% | -4.8% | -1.07% | 27/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 73.05% | -3.66% | 8.53% | 25/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 67.3% | -9.33% | -10.85% | 31/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 75.5% | -1.23% | -0.54% | 27/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 75.91% | -0.04% | 0.11% | 17/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 75.83% | -0.33% | 2.15% | 20/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 74.23% | 1.64% | -2.89% | 17/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 76.44% | 10.56% | 0.65% | 24/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 75.94% | 12.41% | -0.18% | 14/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 76.08% | 15.88% | 4.17% | 14/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 73.03% | 14.3% | 5.63% | 16/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 69.14% | 4.48% | 2.33% | 27/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 67.56% | 1.33% | 2.91% | 20/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 65.65% | -3.76% | 2.75% | 20/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 63.89% | -4.97% | -3.45% | 23/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 66.17% | -3.64% | -0.75% | 21/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 66.67% | -1.09% | -2.26% | 15/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 68.21% | 2.89% | 1.46% | 16/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 67.23% | 4.33% | -2.09% | 12/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |